

ESMO 2017 Industry Satellite Symposium

Biomarkers for Immuno-Oncology: PD-L1 and Beyond

Friday, 8 September, 2017 | 18:00–20:00

Cordoba Auditorium, Hall 4

IFEMA, Feria de Madrid

Madrid, Spain

Welcome letter from the Chair

Dear Colleagues,

You are cordially invited to the Bristol-Myers Squibb industry-sponsored symposium at the ESMO 2017 Congress in Spain, entitled “Biomarkers for Immuno-Oncology: PD-L1 and Beyond.”

We are excited to host this symposium on the evolving landscape of biomarkers in Immuno-Oncology, as biomarkers can play a key role in identifying those patients more likely to respond to therapy. PD-L1 is a marker of the tumour microenvironment that helps to characterize the ongoing intersection between the host immune system and the tumour.

In this symposium, we will discuss the currently available data demonstrating clinical utility of PD-L1 as a predictive biomarker for Immuno-Oncology agents. We will also review the current PD-L1 testing landscape and concordance data. Finally, we will highlight several Immuno-Oncology biomarkers beyond PD-L1, including tumour mutation burden.

Bristol-Myers Squibb and the symposium faculty are committed to clarifying the use and increasing the understanding of biomarkers in Immuno-Oncology by providing this interactive symposium.

Luis Paz-Ares, MD, PhD

Symposium Chair

Hospital Universitario Doce de Octubre
Madrid, Spain

Programme

18:00 Welcome and Introductions

Luis Paz-Ares, MD, PhD

*Hospital Universitario Doce de Octubre
Madrid, Spain*

18:05 An Introduction to PD-L1 and Other Biomarkers in Immuno-Oncology

Luis Paz-Ares, MD, PhD

18:10 Clinical Evidence for Biomarkers Across Tumours

Luis Paz-Ares, MD, PhD

18:35 PD-L1: Practical Implications and Assay Concordance

Julien Adam, MD, PhD

*Institut Gustave Roussy
Villejuif, France*

19:00 Novel Technologies and Future Biomarkers

Fernando López-Ríos, MD, PhD

*Hospital Universitario HM Sanchinarro
Madrid, Spain*

19:35 Discussion and Q&A

Full Panel

19:55 Meeting Close
